<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1629">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03543878</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00101694</org_study_id>
    <nct_id>NCT03543878</nct_id>
  </id_info>
  <brief_title>Stimulating Neural Activity to Improve Blood Flow and Reduce Amyloid: Path to Clinical Trials</brief_title>
  <acronym>FLICKER</acronym>
  <official_title>Stimulating Neural Activity to Improve Blood Flow and Reduce Amyloid: Path to Clinical Trials</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Georgia Institute of Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alzheimer's disease is characterized by the accumulation of toxic proteins in the brain.&#xD;
      Mechanisms to remove these proteins have been the target of many drug trials. This study is&#xD;
      designed to use a device to entrain brain waves to a specific frequency to see if rodent&#xD;
      research can be replicated in humans with mild cognitive impairment. Ten participants will be&#xD;
      recruited from the Emory Alzheimer's Disease Research Center (ADRC) database and assigned to&#xD;
      either treatment for 8 weeks or treatment for 4 weeks. This latter group will serve as the&#xD;
      control group (4 weeks no treatment, 4 weeks treatment). It is hypothesized that exposure to&#xD;
      the gamma oscillations (Flicker) will clear toxic proteins from the brain and increase&#xD;
      cerebral blood flow.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Alzheimer's Disease (AD) is a looming epidemic, with an urgent need for new therapies to&#xD;
      delay or prevent symptom onset and progression. There is growing awareness that clinical&#xD;
      trials must target stage-appropriate pathophysiological mechanisms to effectively develop&#xD;
      disease-modifying treatments. Advances in AD biomarker research have demonstrated changes in&#xD;
      amyloid, brain metabolism, and other pathophysiologies prior to the onset of memory loss,&#xD;
      with some markers possibly changing one or two decades earlier. The brain region responsible&#xD;
      for spatial navigation and memories of experience, the hippocampus, is one of the areas first&#xD;
      affected in Alzheimer's disease (AD) and other memory disorders. Prior research has shown how&#xD;
      coordinated electrical activity across many neurons in the hippocampus represents memories of&#xD;
      experiences and this coordinated activity fails in animal models of AD. The research also&#xD;
      showed that stimulating neurons to produce a specific component of this activity, called&#xD;
      gamma oscillations, reduces AD pathology. The goal of this proposal is to translate this&#xD;
      discovery that stimulating specific patterns of neural activity is neuroprotective from&#xD;
      rodents to humans using a non-invasive approach. This research includes preclinical testing&#xD;
      that will be used to design and justify a multi-site clinical trial to test this approach as&#xD;
      a treatment for AD, for which there are currently no effective therapies.&#xD;
&#xD;
      Cognito Therapeutics has licensed the technology from prior animal research to transition&#xD;
      this work to humans. The company will provide the Flicker devices for conducting this study.&#xD;
      The device is similar to sunglasses and is both comfortable and easy to use.&#xD;
&#xD;
      Ten participants with mild cognitive impairment will be randomly assigned to two study arms.&#xD;
      Although all participants will receive Flicker exposure, half of the participants will&#xD;
      receive the exposure during the entire intervention period (8 weeks of Flicker) while the&#xD;
      other half of the participants will receive Flicker exposure only during the second half of&#xD;
      the intervention period (for 4 weeks of active treatment). During the course of the study,&#xD;
      participants will undergo venous blood draws and lumbar puncture for biomarker analyses at&#xD;
      baseline, midpoint and at the end of the intervention.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 16, 2018</start_date>
  <completion_date type="Actual">February 10, 2020</completion_date>
  <primary_completion_date type="Actual">February 10, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomly assigned to one of two study arms. One group will receive the Flicker exposure for 8 weeks while the other group will receive the active exposure for 4 weeks.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Adherence to Daily Device Use</measure>
    <time_frame>Week 8</time_frame>
    <description>Feasibility of the Flicker intervention is defined as adherence to Flicker exposure, at home, for one hour per day for the duration of the intervention period (4 or 8 weeks). The percentages of completed sessions are presented here.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Maximum Tolerated Stimulation</measure>
    <time_frame>Baseline</time_frame>
    <description>Participants rated their tolerance to Flicker stimulation prior to the study intervention, using a 1 - 5 point Likert scale for each of the 10 levels of brightness (visual stimulation) and each of the 10 levels of loudness (auditory stimulation) after 60 seconds of stimulation at each level. A rating of 1 indicated stimulation &quot;can be withstood and comfortable,&quot; 3 indicated stimulation is &quot;tolerable, but not necessarily comfortable,&quot; and 5 indicated stimulation &quot;cannot be withstood or is uncomfortable.&quot; Ratings of 1, 2, and 3 were considered tolerable. After determining tolerance for auditory and visual stimulation separately, participants were exposed to combined visual and auditory levels beginning one level above the participant's highest stimulation that received a rating of 3 or lower. Tolerability of brightness and loudness levels of combined auditory stimulation was assessed for 60 seconds. See Analysis Population Description for more details.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Flicker for 8 Weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the Flicker exposure during the entire 8-week treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flicker for 4 Weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive the Flicker exposure during the second four weeks of the 8-week treatment period</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Flicker</intervention_name>
    <description>The Flicker intervention is delivered with the GammaSense Stimulation System by Cognito Therapeutics and involves viewing flickering lights at gamma frequency (like a strobe light but faster) to drive gamma oscillations in visual brain areas. The GammaSense Stimulation System is a device consisting of a pair of opaque glasses with a light-emitting diode (LED) illumination on the interior of the glasses. Headphones worn by the user during the stimulation session provide the auditory stimulation. When activated for the treatment session, the device will generate light and sound oscillations at 40 cycles per second (Hz) for 60 minutes. Participants will use the device daily during their active treatment period.</description>
    <arm_group_label>Flicker for 4 Weeks</arm_group_label>
    <arm_group_label>Flicker for 8 Weeks</arm_group_label>
    <other_name>driving gamma</other_name>
    <other_name>GammaSense Stimulation System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must have a subjective memory concern as reported by subject, study partner&#xD;
             or clinician.&#xD;
&#xD;
          -  Meets local criteria for diagnosis of mild cognitive impairment (MCI).&#xD;
&#xD;
          -  Montreal Cognitive Assessment (MoCA) score &gt;15. Exceptions may be made for subjects&#xD;
             with less than 8 years of education at the discretion of the PI.&#xD;
&#xD;
          -  Clinical Dementia Rating = 0.5. Memory Box score must be at least 0.5.&#xD;
&#xD;
          -  General cognition and functional performance sufficiently preserved such that a&#xD;
             diagnosis of Alzheimer's Disease (AD) cannot be made by the physician at the time of&#xD;
             the screening visit.&#xD;
&#xD;
          -  Stable on medications for 4 weeks prior to initiation of study sessions.&#xD;
&#xD;
          -  Geriatric Depression Scale (GDS) â‰¤ than 6.&#xD;
&#xD;
          -  Male or female outpatients aged 50-90 (inclusive).&#xD;
&#xD;
          -  Able to hear without the use of hearing aids.&#xD;
&#xD;
          -  Study partner who lives with the participant and can provide a reliable assessment of&#xD;
             the participant's level of function, is available for all clinic visits, and can serve&#xD;
             as a supervisor/monitor for the home-based Flicker sessions for the duration of the&#xD;
             study.&#xD;
&#xD;
          -  Visual and auditory acuity adequate for neuropsychological testing.&#xD;
&#xD;
          -  Good general health with no diseases expected to interfere with the study.&#xD;
&#xD;
          -  Completed six grades of education or has a good work history (sufficient to exclude&#xD;
             mental retardation).&#xD;
&#xD;
          -  Able to communicate in English with study personnel.&#xD;
&#xD;
          -  Able to understand the nature of the study and provision of written informed consent&#xD;
             prior to conduct of any study procedures.&#xD;
&#xD;
          -  Willing to undergo repeated magnetic resonance imaging (MRI) and positron emission&#xD;
             tomography (PET) scans.&#xD;
&#xD;
          -  Agrees to blood collection for apolipoprotein E (ApoE) and biomarker testing.&#xD;
&#xD;
          -  Agrees to lumbar puncture over the course of the study for the collection of&#xD;
             cerebrospinal fluid (CSF).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any significant neurologic disease other than MCI and suspected incipient AD, such as&#xD;
             Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure&#xD;
             hydrocephalus, brain tumor, progressive supranuclear palsy, poorly controlled seizure&#xD;
             disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma&#xD;
             followed by persistent neurologic deficits or known structural brain abnormalities.&#xD;
&#xD;
          -  Screening/baseline MRI scan with evidence of infection, large vessel infarction or&#xD;
             other focal structural lesions that could account for the memory deficits. Subjects&#xD;
             with multiple lacunes or lacunes in a critical memory structure are excluded.&#xD;
&#xD;
          -  Contraindication to MRI due to pacemakers, aneurysm clips, artificial heart valves,&#xD;
             ear implants, metal fragments or foreign objects in the eyes, skin or body, or&#xD;
             excessive weight.&#xD;
&#xD;
          -  Presence of clinically significant suicide risk, based on the Investigator's judgment&#xD;
             informed by a structured clinician interview. Any suicide attempt within the past 1&#xD;
             year of the screening visit is exclusionary.&#xD;
&#xD;
          -  Major depression, bipolar disorder as described in Diagnostic and Statistical Manual&#xD;
             of Mental Disorders-4 (DSM-IV) within the past 1 year, or history of schizophrenia.&#xD;
&#xD;
          -  Psychotic features, agitation or behavioral problems within the last 3 months which&#xD;
             could lead to difficulty complying with the protocol.&#xD;
&#xD;
          -  History of alcohol or substance abuse or dependence within the past 2 years (DSM-IV&#xD;
             criteria).&#xD;
&#xD;
          -  Known history of epilepsy or migraines, which may be exacerbated by study&#xD;
             intervention.&#xD;
&#xD;
          -  History of narrow angle (acute angle) glaucoma.&#xD;
&#xD;
          -  Current use of warfarin or other blood thinners (exclusionary for lumbar puncture).&#xD;
&#xD;
          -  Inability to obtain initial CSF sample.&#xD;
&#xD;
          -  Current use of Namenda (memantine).&#xD;
&#xD;
          -  Current use of medications that lower seizure threshold, including Wellbutrin,&#xD;
             Ciprofloxacin, Levofloxacin, Seroquel, Phenergan, and Sumatriptan.&#xD;
&#xD;
          -  Current use of anti-psychotic medication.&#xD;
&#xD;
          -  CSF profile inconsistent with underlying Alzheimer's Disease pathology.&#xD;
&#xD;
          -  Reasonable likelihood for non-compliance with the protocol or any other reason, in the&#xD;
             opinion of the investigator, prohibits enrollment of subject into the study.&#xD;
&#xD;
          -  Exceptions to these guidelines may be considered on a case-by-case basis at the&#xD;
             discretion of the protocol director.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Lah, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>12 Executive Park Drive</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>May 21, 2018</study_first_submitted>
  <study_first_submitted_qc>May 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2018</study_first_posted>
  <results_first_submitted>January 28, 2021</results_first_submitted>
  <results_first_submitted_qc>February 26, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 2, 2021</results_first_posted>
  <last_update_submitted>February 26, 2021</last_update_submitted>
  <last_update_submitted_qc>February 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>James Lah</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 4, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/78/NCT03543878/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from the Emory Cognitive Neurology Clinic and the Emory Goizueta Alzheimer's Disease Research Center (ADRC), in Atlanta, Georgia. Participant enrollment began on November 16, 2018 and study follow up was completed on February 10, 2020.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Flicker/Flicker</title>
          <description>Participants receiving the Flicker exposure for the first 4 weeks of the study and the second four weeks of the study, for a total of 8 weeks of treatment.</description>
        </group>
        <group group_id="P2">
          <title>No Flicker/Flicker</title>
          <description>Participants receiving no exposure to Flicker for the first 4 weeks of the study and then receiving the Flicker exposure for the second four weeks of the study, for a total of 4 weeks of treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Flicker/Flicker</title>
          <description>Participants receiving the Flicker exposure for the first 4 weeks of the study and the second four weeks of the study, for a total of 8 weeks of treatment.</description>
        </group>
        <group group_id="B2">
          <title>No Flicker/Flicker</title>
          <description>Participants receiving no exposure to Flicker for the first 4 weeks of the study and then receiving the Flicker exposure for the second four weeks of the study, for a total of 4 weeks of treatment.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72" spread="8.15"/>
                    <measurement group_id="B2" value="70.6" spread="6.54"/>
                    <measurement group_id="B3" value="71.3" spread="7.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Adherence to Daily Device Use</title>
        <description>Feasibility of the Flicker intervention is defined as adherence to Flicker exposure, at home, for one hour per day for the duration of the intervention period (4 or 8 weeks). The percentages of completed sessions are presented here.</description>
        <time_frame>Week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Flicker/Flicker</title>
            <description>Participants receiving the Flicker exposure for the first 4 weeks of the study and the second four weeks of the study, for a total of 8 weeks of treatment.</description>
          </group>
          <group group_id="O2">
            <title>No Flicker/Flicker</title>
            <description>Participants receiving no exposure to Flicker for the first 4 weeks of the study and then receiving the Flicker exposure for the second four weeks of the study, for a total of 4 weeks of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Adherence to Daily Device Use</title>
          <description>Feasibility of the Flicker intervention is defined as adherence to Flicker exposure, at home, for one hour per day for the duration of the intervention period (4 or 8 weeks). The percentages of completed sessions are presented here.</description>
          <units>percentage of adherence to treatment</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.55" spread="2.92"/>
                    <measurement group_id="O2" value="95.37" spread="4.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Maximum Tolerated Stimulation</title>
        <description>Participants rated their tolerance to Flicker stimulation prior to the study intervention, using a 1 - 5 point Likert scale for each of the 10 levels of brightness (visual stimulation) and each of the 10 levels of loudness (auditory stimulation) after 60 seconds of stimulation at each level. A rating of 1 indicated stimulation &quot;can be withstood and comfortable,&quot; 3 indicated stimulation is &quot;tolerable, but not necessarily comfortable,&quot; and 5 indicated stimulation &quot;cannot be withstood or is uncomfortable.&quot; Ratings of 1, 2, and 3 were considered tolerable. After determining tolerance for auditory and visual stimulation separately, participants were exposed to combined visual and auditory levels beginning one level above the participant's highest stimulation that received a rating of 3 or lower. Tolerability of brightness and loudness levels of combined auditory stimulation was assessed for 60 seconds. See Analysis Population Description for more details.</description>
        <time_frame>Baseline</time_frame>
        <population>Outcome Measure Description continued: Tolerability at the highest level of &quot;10&quot; was scored as 100. Maximum tolerated levels for visual alone, auditory alone, visual combined, and auditory combined were averaged for the Flicker/Flicker and No Flicker/Flicker groups.</population>
        <group_list>
          <group group_id="O1">
            <title>All Study Participants</title>
            <description>Participants receiving the Flicker exposure in either the Flicker/Flicker or No Flicker/Flicker study arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Maximum Tolerated Stimulation</title>
          <description>Participants rated their tolerance to Flicker stimulation prior to the study intervention, using a 1 - 5 point Likert scale for each of the 10 levels of brightness (visual stimulation) and each of the 10 levels of loudness (auditory stimulation) after 60 seconds of stimulation at each level. A rating of 1 indicated stimulation &quot;can be withstood and comfortable,&quot; 3 indicated stimulation is &quot;tolerable, but not necessarily comfortable,&quot; and 5 indicated stimulation &quot;cannot be withstood or is uncomfortable.&quot; Ratings of 1, 2, and 3 were considered tolerable. After determining tolerance for auditory and visual stimulation separately, participants were exposed to combined visual and auditory levels beginning one level above the participant's highest stimulation that received a rating of 3 or lower. Tolerability of brightness and loudness levels of combined auditory stimulation was assessed for 60 seconds. See Analysis Population Description for more details.</description>
          <population>Outcome Measure Description continued: Tolerability at the highest level of &quot;10&quot; was scored as 100. Maximum tolerated levels for visual alone, auditory alone, visual combined, and auditory combined were averaged for the Flicker/Flicker and No Flicker/Flicker groups.</population>
          <units>percentage of tolerated stimulation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visual alone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" spread="9.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Auditory alone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" spread="4.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visual when combined with auditory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" spread="12.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Auditory when combined with visual</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" spread="18.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected during the time when participants were receiving the Flicker intervention (up until Week 8 for the Flicker/Flicker group and until Week 4 for the No Flicker/Flicker group).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Flicker/Flicker</title>
          <description>Participants receiving the Flicker exposure for the first 4 weeks of the study and the second four weeks of the study, for a total of 8 weeks of treatment.</description>
        </group>
        <group group_id="E2">
          <title>No Flicker/Flicker</title>
          <description>Participants receiving no exposure to Flicker for the first 4 weeks of the study and then receiving the Flicker exposure for the second four weeks of the study, for a total of 4 weeks of treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <description>possibly related to study treatment</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <description>not related to study treatment</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>possibly related to study treatment</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>possibly related to study treatment</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Double vision</sub_title>
                <description>not related to study treatment</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <description>not related to study treatment</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Gastrointestinal problems</sub_title>
                <description>not related to study treatment</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <description>not related to study treatment</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dog bite</sub_title>
                <description>not related to study treatment</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Leg, arm, joint pain</sub_title>
                <description>not related to study treatment</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <description>not related to study treatment</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Skin growth on neck</sub_title>
                <description>not related to study treatment</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <description>not related to study treatment</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Annabelle C. Singer, PhD</name_or_title>
      <organization>Georgia Institute of Technology</organization>
      <phone>510-501-9659</phone>
      <email>asinger@gatech.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

